Welcome to the forefront of conversational AI as we explore the fascinating world of AI chatbots in our dedicated blog series. Discover the latest advancements, applications, and strategies that propel the evolution of chatbot technology. From enhancing customer interactions to streamlining business processes, these articles delve into the innovative ways artificial intelligence is shaping the landscape of automated conversational agents. Whether you’re a business owner, developer, or simply intrigued by the future of interactive technology, join us on this journey to unravel the transformative power and endless possibilities of AI chatbots.
Let Healthcare Dive’s free newsletter keep you informed, straight from your inbox.
The planned acquisition comes as wearable firms push to up their healthcare offerings.
First published on
Oura plans to offer Counsel’s platform within the Oura app. The pairing with Oura can give physicians context, biometric data and member engagement, Counsel CEO and founder Dr. Muthu Alagappan said in a statement.
Counsel’s platform uses AI agents to take a person’s medical history, retrieve guidelines, review records and detect emergencies. Users start by chatting with the AI, which provides guidance based on this information, prior interactions and biometric data. Patients can choose to add a physician to the chat, who can provide a diagnosis, prescriptions or referrals as appropriate.
Oura expects to close the acquisition before the end of the year. It is subject to purchase price adjustments and customary closing conditions.
In September, Oura had sought to raise up to $2.2 billion in a planned initial public offering. However, the company chose to delay the IPO later that month, citing market uncertainty.
Get the free daily newsletter read by industry experts
Sen. Chuck Grassley, R-Iowa, suggested Congress could once again move to overhaul PBMs’ controversial business practices after legislators pass President Donald Trump’s conservative megabill this summer.
The FDA said it’s sending letters to drugmakers demanding they take down or modify ads that don't comply with federal guidelines, out of concern consumers aren’t seeing a “fair balance” of risks and benefits in drug ads.
Subscribe to Healthcare Dive for top news, trends & analysis
Sign up for the free newsletter.
Interested? Explore more of what has to offer.
Thanks for signing up! Please keep an eye out for a confirmation email from [email protected] To ensure we make it into your inbox regularly, add us to your allow list, mark us as a safe sender, or add us to your address book. Check out more from
Get the free daily newsletter read by industry experts
The agency said it would increase the number of MA plan audits and complete its backlog of reviews by investing in technology and growing its medical coding workforce.
The FDA said it’s sending letters to drugmakers demanding they take down or modify ads that don't comply with federal guidelines, out of concern consumers aren’t seeing a “fair balance” of risks and benefits in drug ads.
The free newsletter covering the top industry headlines